J. Safra Sarasin Holding AG Raises Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

J. Safra Sarasin Holding AG grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 87.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,189 shares of the medical equipment provider’s stock after purchasing an additional 11,765 shares during the period. J. Safra Sarasin Holding AG’s holdings in Zimmer Biomet were worth $2,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Stifel Financial Corp grew its stake in Zimmer Biomet by 10.8% in the 4th quarter. Stifel Financial Corp now owns 96,032 shares of the medical equipment provider’s stock worth $10,144,000 after acquiring an additional 9,341 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Zimmer Biomet by 111.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,458 shares of the medical equipment provider’s stock worth $1,738,000 after purchasing an additional 8,691 shares during the period. Natixis bought a new stake in Zimmer Biomet during the 4th quarter valued at $12,881,000. Ossiam grew its position in shares of Zimmer Biomet by 6.4% during the 4th quarter. Ossiam now owns 6,548 shares of the medical equipment provider’s stock worth $692,000 after buying an additional 396 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Zimmer Biomet by 43.6% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 9,449 shares of the medical equipment provider’s stock valued at $998,000 after acquiring an additional 2,871 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent research reports. Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Down 1.6 %

NYSE:ZBH opened at $96.38 on Tuesday. The firm has a market capitalization of $19.07 billion, a P/E ratio of 21.66, a PEG ratio of 1.95 and a beta of 0.84. The company’s fifty day moving average price is $105.87 and its 200-day moving average price is $106.68. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm posted $2.20 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.